Surmodics is facing a challenge to its proposed merger with private equity firm GTCR but remains determined to finalize the deal. The company expressed confidence in the merger's rationale and its potential benefits for shareholders, customers, and patients. Surmodics has been working with the Federal Trade Commission (FTC) to obtain regulatory approval and is disappointed by the FTC's decision to initiate litigation against the merger, which Surmodics believes is pro-competitive.

In light of ongoing regulatory changes, businesses are encouraged to stay informed about potential risks. MLex offers specialized reporting and analysis on various regulatory matters, including antitrust issues, mergers and acquisitions, trade, data privacy, and technology.

MLex provides daily newsletters and custom alerts tailored to specific industries and topics, ensuring that organizations are aware of critical developments. Their expert journalists deliver predictive analysis across multiple regions, including North America, Europe, Latin America, and Asia-Pacific.

Additionally, MLex curates case files that compile news, analysis, and source documents, allowing businesses to track regulatory changes effectively. Interested parties can experience MLex's offerings with a 14-day free trial.